Statin-Associated Diabetes Risk in Pre-Diabetic Men Over 65

Risk Hierarchy by Statin Type

High-intensity statins (atorvastatin 80mg, rosuvastatin 20-40mg) have approximately 3 excess cases of incident diabetes per 1,000 individuals treated for 1 year compared to placebo (NNH=332 per year) 1
Pitavastatin has shown conflicting results, with some studies suggesting it may have a neutral or potentially beneficial effect on glucose metabolism compared to other statins 1

High-intensity statin therapy is associated with 2 excess cases of incident diabetes per 1,000 individuals treated for 1 year compared with moderate-intensity statins (NNH=498 per year) 1
High-intensity statins showed a 24% increased risk of worsening glycemia (RR 1.24; 95% CI 1.06-1.44) compared to 10% with low-to-moderate intensity statins 1

Despite the increased diabetes risk, the cardiovascular benefit of statins generally outweighs the diabetes risk in most patients 1, 2
High-intensity statin therapy results in 6.5 fewer major cardiovascular events per 1,000 individuals treated for 1 year compared with moderate-intensity statin therapy (NNT=155 per year) 1
The American College of Cardiology recommends that for individuals above 75 years old, moderate-intensity statins may be reasonable for primary prevention, but should be carefully considered based on risk factors and comorbidities 3

Baseline assessment of glycemic parameters before starting statin therapy is essential 1
In patients who develop diabetes while on statin therapy, the statin should typically be continued with appropriate diabetes management rather than discontinued, as cardiovascular benefits generally outweigh risks 1, 2

Failing to monitor glycemic parameters in pre-diabetic men over 65 who are starting statin therapy 1
Discontinuing statins entirely due to concerns about diabetes risk, rather than adjusting the type or intensity of statin therapy 1, 2